What is IGF-1 LR3?
IGF-1 LR3 — Long R3 Insulin-like Growth Factor 1 — is a synthetic 83-amino acid analog of endogenous IGF-1, engineered to overcome one of the primary limitations of the native peptide: its near-complete sequestration by IGF-binding proteins (IGFBPs). With two targeted structural changes that reduce IGFBP affinity by roughly 1000-fold, IGF-1 LR3 achieves an estimated half-life of 20–30 hours compared to the few minutes of native IGF-1 — and with it, substantially more time for IGF-1 receptor engagement and downstream PI3K/Akt/mTOR signaling. Research interest spans muscle fiber hyperplasia (the formation of new fibers, distinct from simple hypertrophy), protein synthesis, fat metabolism, and body recomposition.
What IGF-1 LR3 Is
Insulin-like Growth Factor 1 (IGF-1) is a 70-amino acid peptide produced primarily in the liver in response to growth hormone (GH) signaling. It is the downstream mediator of many of GH's anabolic effects — including protein synthesis, satellite cell activation, and fat metabolism — acting through its own tyrosine kinase receptor, the IGF-1R.
The problem with using native IGF-1 as a research tool is that it barely exists as a free peptide in biological systems. Six different IGF-binding proteins (IGFBPs 1–6) compete for it, collectively sequestering 95–99% of circulating IGF-1 within minutes of its production. The result: a half-life measured in minutes and a tiny free fraction capable of receptor activation.
IGF-1 LR3 addresses this by modifying two features of the native sequence:
"Long" — the 13-amino acid N-terminal extension: Appending a 13-residue extension to the N-terminus sterically interferes with the binding interface that IGFBPs use to sequester IGF-1.
"R3" — arginine substitution at position 3: Replacing the glutamic acid at position 3 with arginine further disrupts the IGFBP binding surface without substantially altering IGF-1R affinity.
IGF-1 LR3 vs Native IGF-1
| Parameter | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Amino acid length | 70 aa | 83 aa (+13 N-terminal extension) |
| Position 3 | Glutamic acid (Glu) | Arginine (Arg) — the "R3" |
| IGFBP affinity | High (95–99% bound) | ~1000-fold reduced |
| Free (bioactive) fraction | 1–5% | Substantially higher |
| Biological half-life | Minutes | ~20–30 hours |
| IGF-1R affinity | Reference | Comparable (slight reduction vs native) |
| Post-reconstitution stability | Very low | Reduced — use within 1–2 weeks or aliquot-freeze |
Mechanism of Action
IGF-1 LR3 signals through the same receptor as native IGF-1: the IGF-1R, a receptor tyrosine kinase expressed broadly across muscle, bone, liver, adipose, and neuronal tissues.
IGF-1R activation: Binding of IGF-1 LR3 to IGF-1R triggers receptor dimerization and autophosphorylation of tyrosine residues in the intracellular kinase domain. This recruits IRS-1/IRS-2 (insulin receptor substrate) adaptor proteins, which serve as docking platforms for the two primary downstream cascades:
PI3K → Akt → mTOR pathway (anabolic): Phosphoinositide 3-kinase (PI3K) generates PIP3, which recruits and activates Akt (protein kinase B). Akt phosphorylates mTORC1, which drives ribosomal protein S6 kinase (S6K1) and 4E-BP1 — the core translational machinery for protein synthesis. This is the primary pathway through which IGF-1 LR3's anabolic research effects are studied.
MAPK/ERK pathway (proliferative): Parallel activation of the Ras → Raf → MEK → ERK cascade drives cell proliferation and differentiation. This arm of IGF-1R signaling is particularly relevant to satellite cell (muscle stem cell) research.
Hyperplasia vs Hypertrophy: Why the Distinction Matters
Most mechanisms of muscle growth studied in sports science involve hypertrophy: existing muscle fibers increase in cross-sectional area in response to mechanical load and anabolic signaling, largely via the mTOR pathway. The fiber count stays roughly constant; the fibers just get bigger.
Hyperplasia is different: it involves the activation of satellite cells — muscle-resident stem cells that can proliferate and fuse to form entirely new muscle fibers. If IGF-1 LR3 stimulates satellite cell proliferation and fusion at sufficient scale, it could theoretically increase the total number of muscle fibers, not just their size. This would represent a qualitatively different adaptation.
Research on this distinction in mammalian models is the primary reason IGF-1 LR3 occupies a distinct category from other anabolic research compounds. The ERK/MAPK arm of IGF-1R signaling (which drives proliferation) and the PI3K/Akt/mTOR arm (which drives anabolic protein synthesis and anti-apoptotic survival) can be studied in parallel to map their relative contributions to muscle fiber outcomes.
| Process | Definition | Pathway | IGF-1 LR3 Research Link |
|---|---|---|---|
| Hypertrophy | Existing fiber enlargement | PI3K → Akt → mTOR → S6K1/4E-BP1 | Well-studied; protein synthesis increase |
| Hyperplasia | New fiber formation | MAPK/ERK → satellite cell proliferation → myogenesis | Active research area; satellite cell activation models |
Research Applications
| Research Area | Pathway | Notes |
|---|---|---|
| Muscle protein synthesis | PI3K/Akt/mTOR | mTORC1 activation → S6K1/4E-BP1 → translation |
| Satellite cell activation | MAPK/ERK | Muscle stem cell proliferation and myogenesis studies |
| Muscle fiber hyperplasia | Satellite cell → myoblast → fiber fusion | Distinct from hypertrophy; requires satellite cell models |
| Fat metabolism | IGF-1R → Akt → GLUT4 trafficking | Glucose uptake, lipolysis, and body recomposition endpoints |
| GH axis downstream characterization | IGF-1R independent of GH pulsatility | Studied alongside CJC-1295/Ipamorelin or Tesamorelin to map GH → IGF-1 → receptor axis |
Because IGF-1 LR3 acts downstream of GH-axis secretagogues like CJC-1295 + Ipamorelin or Tesamorelin, researchers studying the full GH/IGF-1 signaling cascade sometimes use IGF-1 LR3 to characterize receptor-level outcomes independently of pituitary GH pulsatility. See our What is CJC-1295? guide and Ipamorelin vs CJC-1295 comparison for context on the upstream GH axis.
Reconstitution & Stability
IGF-1 LR3 requires more careful handling than most smaller research peptides due to its reduced post-reconstitution stability.
Standard protocol for the 1mg vial: Add 1 mL Bacteriostatic Water for a concentration of 1000 mcg/mL (1 mg/mL). Inject BAC Water slowly down the vial wall and swirl gently — do not shake, as mechanical stress can disrupt the disulfide bonds that maintain the peptide's three-dimensional structure.
For full reconstitution parameters and a dosing calculator that computes exact draw volumes, visit our Reconstitution Guide and Dosing Calculator. For broader peptide storage best practices, see our Peptide Storage 101 guide.